Gail Rae Garwood

In this episode of the Psychedelic Spotlight podcast, we speak with Trevor Millar, a distinguished Advisor to NeonMind Biosciences, an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions. In our conversation with Trevor, we have the opportunity to discuss some of the psychedelic-based treatments NeonMind is currently focused on developing to help tackle this very serious health condition. Obesity is one of the more prevalent health conditions today affecting millions of individuals worldwide. The World Health Organization has claimed that obesity has reached epidemic proportions globally with at least 2.8 million people dying each year as a result of being overweight or obese. *You can find NeonMind Biosciences trading on the Canadian securities exchange under the symbol $NEON. To learn more about the company, visit their website: NeonMindBiosciences.com*Subscribe to our newsletter to get the latest industry news: PsychedelicSpotlight.com

In today’s episode of the Psychedelic Spotlight podcast, the Psychedelic Investor, James Hallifax interviews Ian McDonald, CEO and Director of Bright Minds Biosciences. For any investors out there, you can find Bright Minds Biosciences trading on the Canadian Securities Exchange under the symbol $DRUG and on the American OTC market under the symbol $BMBIF. In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain. Bright Minds is a company working on second and third generation psychedelics to treat a variety of ailments including depression, PTSD, epilepsy, addiction and more. The driving philosophy is that while classic psychedelics such as psilocybin and LSD do show great potential to be used in a therapy setting to treat mental health issues, the compounds also have limitations. At Bright Minds, the goal is to engineer completely new compounds, often based on the structure of classical psychedelics, that keep the benefits of said drugs while doing away with potential negatives. Important to note is that while psychedelic derived drugs are a focus of the company, they also are creating non-psychedelic compounds for a variety of ailments, including different forms of addiction. *To learn more about Bright Minds Biosciences, visit their website: BrightMindsBio.com*Subscribe to our newsletter to get the latest industry news: PsychedelicSpotlight.com

Pressure Biosciences, Inc. (OTCQB: PBIO) CEO Ric Schumacher was on Investor Town Hall Show discussing the latest company developments.

Our Guest: Dr. Jonathan Stein, Chief Science Officer & Medical Director at Tesis BiosciencesWhat you'll get out of this episode:Stein's backgroundA background of Tesis Biosciences and the biggest challenges they're addressing for their customersWhy understanding genomics is important for the future of healthWhy understanding genetics is key to highlighting vulnerabilities to infectious diseasesWhat the genetics field can learn from Covid-19 to apply in the mitigation of future pandemicsWhere genomics and genetic testing will have the largest impact in preventative care in the coming yearsOur sponsors for this episode are BlocHealth, Curation Health, ChenMed & MediTelecare.BlocHealth is building the ecosystem of services and solutions to power the future of healthcare. For more information, please go to www.blochealth.com & follow BlocHealth on social media - @blochealth"Curation Health’s advanced clinical decision support platform seamlessly integrates into the electronic health record and leverages more than 750 proven clinical and quality rules. With this intelligent point-of-care platform, you can power a scalable risk adjustment process and amplify quality program performance." For more information, please go to www.curationhealthcare.com & follow Curation Health on social media - @curationhealth"ChenMed brings concierge-style medicine and better health outcomes to the neediest populations – moderate-to-low income seniors with complex chronic diseases. For more information, please go to www.chenmed.com & follow ChenMed on social media - @chenmed"MediTelecare provides behavioral telemedicine services to residents of skilled nursing and assisted living facilities, using state-of-the-art telehealth technology." For more information, please go to www.meditelecare.com & follow MediTelecare on social media – @meditelecareTo learn more about Tesis Biosciences please use the links below:- Website - LinkedInAlso, be sure to follow Slice of Healthcare on our social channels:- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter